Goldman Sachs Group Inc Tarsus Pharmaceuticals, Inc. Transaction History

Goldman Sachs Group Inc

  • $613 Billion
  • Q4 2024

A detailed history of Goldman Sachs Group Inc transactions in Tarsus Pharmaceuticals, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 318,730 shares of TARS stock, worth $16.5 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
318,730
Previous 268,775 18.59%
Holding current value
$16.5 Million
Previous $8.84 Million 99.64%
% of portfolio
0.0%
Previous 0.0%

Shares

20 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 11, 2025
BUY
$32.27 - $55.37 $1.61 Million - $2.77 Million
49,955 Added 18.59%
318,730 $17.6 Million
Q3 2024

Nov 14, 2024
BUY
$21.54 - $34.6 $1.36 Million - $2.19 Million
63,224 Added 30.76%
268,775 $8.84 Million
Q2 2024

Aug 13, 2024
BUY
$25.17 - $38.73 $45,834 - $70,527
1,821 Added 0.89%
205,551 $5.59 Million
Q1 2024

May 15, 2024
SELL
$19.61 - $39.22 $661,033 - $1.32 Million
-33,709 Reduced 14.2%
203,730 $7.41 Million
Q4 2023

Feb 13, 2024
BUY
$12.98 - $20.73 $1.78 Million - $2.85 Million
137,377 Added 137.29%
237,439 $4.81 Million
Q3 2023

May 14, 2024
SELL
$14.75 - $24.62 $2.03 Million - $3.38 Million
-137,377 Reduced 57.86%
100,062 $1.78 Million
Q3 2023

Nov 14, 2023
BUY
$14.75 - $24.62 $340,872 - $568,968
23,110 Added 30.03%
100,062 $1.78 Million
Q2 2023

May 14, 2024
BUY
$11.57 - $19.63 $559,837 - $949,836
48,387 Added 169.39%
76,952 $1.39 Million
Q2 2023

Aug 14, 2023
BUY
$11.57 - $19.63 $559,837 - $949,836
48,387 Added 169.39%
76,952 $1.39 Million
Q1 2023

May 14, 2024
SELL
$11.92 - $16.27 $323,067 - $440,965
-27,103 Reduced 48.69%
28,565 $359,000
Q1 2023

May 11, 2023
SELL
$11.92 - $16.27 $323,067 - $440,965
-27,103 Reduced 48.69%
28,565 $359,000
Q4 2022

May 14, 2024
SELL
$14.12 - $18.72 $749,207 - $993,283
-53,060 Reduced 48.8%
55,668 $816,000
Q4 2022

Feb 13, 2023
SELL
$14.12 - $18.72 $749,207 - $993,283
-53,060 Reduced 48.8%
55,668 $816,000
Q3 2022

May 14, 2024
BUY
$14.08 - $18.5 $141,053 - $185,333
10,018 Added 10.15%
108,728 $1.86 Million
Q3 2022

Nov 10, 2022
BUY
$14.08 - $18.5 $141,053 - $185,333
10,018 Added 10.15%
108,728 $1.86 Million
Q2 2022

May 14, 2024
SELL
$11.08 - $19.08 $1.54 Million - $2.65 Million
-138,729 Reduced 58.43%
98,710 $1.44 Million
Q2 2022

Aug 15, 2022
BUY
$11.08 - $19.08 $780,630 - $1.34 Million
70,454 Added 249.34%
98,710 $1.44 Million
Q1 2022

May 16, 2022
BUY
$14.49 - $24.28 $2,216 - $3,714
153 Added 0.54%
28,256 $475,000
Q4 2021

Feb 14, 2022
BUY
$21.21 - $29.68 $34,423 - $48,170
1,623 Added 6.13%
28,103 $632,000
Q3 2021

Nov 10, 2021
BUY
$21.45 - $29.22 $567,996 - $773,745
26,480 New
26,480 $571,000

Others Institutions Holding TARS

# of Institutions
200
Shares Held
40.4M
Call Options Held
72.7K
Put Options Held
313K
View Full List

About Tarsus Pharmaceuticals, Inc.

TARS Quotes by TradingView
  • Ticker TARS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 26,658,500
  • Market Cap $1.38B
  • Description
  • Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as...
More about TARS
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email